Eli Lilly acquired struggling biotech startup Kelonia Therapeutics for $3.2 billion, a deal that underscores the high stakes and potential rewards in cancer cell therapy development. This acquisition signals to developers and tech professionals the continued interest from major pharmaceuticals in innovative but financially precarious startups with promising therapeutic technologies. Watch for how Eli Lilly integrates Kelonia’s cell therapies into its portfolio and their impact on future cancer treatments.
Read the full article at STAT News
Want to create content about this topic? Use Nemati AI tools to generate articles, social posts, and more.
2
alinemati1983-6987Written by alinemati1983-6987
